Stockscreener 앱 받기
7.47
0.40%
0.03
시간 외 거래:
7.50
0.03
+0.40%
Bausch Health Companies Inc 주식(BHC)의 최신 뉴스
Xifaxan selected for CMS drug price talks in 2027 - MSN
Bausch Health Companies (NYSE:BHC) Sees Strong Trading VolumeHere's Why - MarketBeat
Bausch Health acknowledges XIFAXAN selection for Medicare Negotiation Program - MSN
Xifaxan selected for CMS drug price talks in 2027 By Investing.com - Investing.com South Africa
Bausch Health Q3 Earnings and Revenues Top, Xifaxan Boosts Sales - MSN
Bausch Health Statement on Selection of XIFAXAN(R)?(rifaximin) for Inflation Reduction Act's Medicare Negotiation Program - WICZ
Bausch Health’s XIFAXAN Selected for Medicare Price Negotiation - TipRanks
Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act's Medicare Negotiation Program - Yahoo Finance
Topical Drugs Market Trends Analysis Report 2025-2030, with - GlobeNewswire
Topical Drugs Market Trends Analysis Report 2025-2030, with Profiles of Bayer, Cipla, GSK, Novartis, Bausch Health Companies, Hisamitsu Pharmaceuticals, Merck, Glenmark Pharmaceuticals & MedPharm - Yahoo Finance
FDA grants tentative approval for Amneal generic of Bausch Health's Xiafan - MSN
Innovations in Scar Treatment Market: What to Expect by 2031 | Bausch Health Companies Inc., Candela Medical - EIN News
Bausch Health Companies Inc. (NYSE:BHC) Receives $7.75 Average PT from Analysts - MarketBeat
Deal Watch: Bausch Companies Set Hectic Pace At J.P. Morgan With Five Deals - News & Insights
Actinic Keratosis Market Investment Opportunities: A Guide to 2031 | Almirall, S.A, Bausch Health Companies Inc. - openPR
Acne Vulgaris Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, MOA, ROA by DelveInsight | Dermata Therapeutics, AstraZeneca, Novartis, UCB Pharma, Incyte Inc., Galderma - The Globe and Mail
George Medicines signs exclusive licensing agreement with Bausch Health to commercialize GMRx2 in Canada, Mexico, Columbia and Central America - The Manila Times
George Medicines signs exclusive licensing agreement with - GlobeNewswire
Barclays PLC Cuts Position in Bausch Health Companies Inc. (NYSE:BHC) - Defense World
Is Bausch Health Companies (BHC) the Best Medical Stock to Buy Under $20? - Yahoo Finance
12 Best Medical Stocks To Buy Under $20 - Insider Monkey
Bausch Health Companies (TSE:BHC) Trading Up 3%Here's Why - MarketBeat
Here's Why Bausch Health (BHC) is a Strong Momentum Stock - Yahoo Finance
Myopia And Presbyopia Treatment Market Future Business - openPR
Botanical and Plant-Derived Drugs Market to Grow by USD 18.66 Billion (2025-2029), Driven by Government Initiatives and AI Impact on Market TrendsTechnavio - The Malaysian Reserve
Bausch Health Companies Inc (BHC-T) QuotePress Release - The Globe and Mail
124,534 Shares in Bausch Health Companies Inc. (NYSE:BHC) Bought by Range Financial Group LLC - MarketBeat
Atopic Dermatitis Pipeline Review 2024: Clinical Trials Update and Market Impact by DelveInsight | GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regeneron Pharma, Abbvie, Allergan PLC, Bausch Health - Barchart
Scar Treatment Market Overall Study Report 2025-2032 | Bausch - openPR
Geode Capital Management LLC Increases Holdings in Bausch Health Companies Inc. (NYSE:BHC) - MarketBeat
Non-surgical Skin Tightening Market Report 2024-2029, with - GlobeNewswire
$2.5+ Bn Body Contouring Treatments MarketsGlobal Analysis and Forecasts to 2029 with AbbVie, Inmode), Bausch Health, Cynosure Lutronic, and Sisram Medical Leading - GlobeNewswire
Face Treatment Market Key Players AnalysisLutron, Bausch - openPR
BAUSCH HEALTH COMPANIES INC. DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Bausch Health Companies Inc. (NYSE:BHC) - AccessWire
Bausch Health Companies (BHC) Shares Cross Above 200 DMA - Nasdaq
Bausch Health Companies Inc.'s (NYSE:BHC) Path To Profitability - Simply Wall St
T-cell Lymphoma Market Key Players Analysis4SC AG, Acrotech - openPR
Periodontal Disease Treatment Market Dynamics and Key Trends: - openPR
Bausch Health Companies Inc. (NYSE:BHC) Receives $7.75 Consensus Target Price from Analysts - MarketBeat
Bausch + Lomb confirms potential sale is 'one of several options being explored' - MSN
Zacks Research Issues Optimistic Outlook for BHC Earnings - MarketBeat
FY2024 EPS Estimates for TSE:BHC Raised by Analyst - MarketBeat
Zacks Research Issues Optimistic Forecast for BHC Earnings - MarketBeat
Is Bausch Health Companies (BHC) Among Billionaire Paul Singer’s Top Long-Term Stock Picks? - Yahoo Finance
Bausch Health Companies Inc. (NYSE:BHC) Stock Position Reduced by Franklin Resources Inc. - MarketBeat
Bausch Health's SWOT analysis: debt woes cloud strong q3 for diverse pharma stock - Investing.com
Canada: Bausch Health responds to rumours of potential sale of Bausch + Lomb - Investors in Healthcare
Bausch Health Companies Inc. (NYSE:BHC) Short Interest Up 9.9% in November - MarketBeat
Bausch + Lomb responds to rumors of a potential sale - The Pharma Letter
Bausch Health tanks 23.3% on unconfirmed report of bankruptcy filing - MSN
Bausch And Lomb Says Potential Sale In The Works - Law360
2.14%
자본화:
|
볼륨(24시간):